Biomarker Capture Platform Articles & Analysis
3 articles found
Nanostics’ biomarker and machine learning-powered test, ClarityDX Prostate®, received a CE-IVD Mark. A CE-IVD Mark is required for all in vitro diagnostic (IVD) devices to be placed in the European Economic Area, Iceland, Norway, and Liechtenstein and allows Nanostics to market and sell ClarityDX Prostate® in these countries. The ClarityDX Prostate® test provides patients ...
Introducing Beacon Biosignals: a neurotechnology company founded to develop machine learning-enabled EEG neurobiomarkers and accelerate precision medicine for any disease state affecting the brain Founded by MD/PhDs and engineers from Harvard and MIT, Beacon is propelled by the vision of a computing platform designed to scale the interrogation of large brain datasets with unprecedented ...
Edmonton, Alberta - Nanostics Inc., a diagnostic healthcare company that focuses on developing tests to determine a patient's disease risk, announced today plans to develop and validate ClarityDX COVID-19; a simple blood test to predict the severity of COVID-19 disease in patients. Nanostics, in collaboration with the Canadian BioSample Repository (CBSR) at the University of Alberta and Century ...